ISRCTN49221770 https://doi.org/10.1186/ISRCTN49221770

# A Randomised Study of MVP (Mitomycin-C, Vinblastine and Moderate Dose Cisplatin) Three versus Six Cycles in Advanced Non-Small Cell Lung Cancer

**Submission date**
19/08/2002

**Recruitment status**
No longer recruiting

**Registration date**
19/08/2002

**Overall study status**
Completed

**Last Edited**
10/10/2012

**Condition category**
Cancer

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[ ] Results
[ ] Individual participant data
[ ] Record updated in last year

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr - -

**Contact details**
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

## Additional identifiers

**Protocol serial number**
L14

## Study information

**Scientific Title**

## Study objectives
Not provided at time of registration

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
Not provided at time of registration

## Study design
Randomised controlled trial

## Primary study design
Interventional

## Study type(s)
Not Specified

## Health condition(s) or problem(s) studied
Lung (non-small cell) cancer

## Interventions
All patients receive chemotherapy with MVP (mitomycin-C, vinblastine and moderate dose cisplatin) repeated every 21 days for three courses. Mitomycin-C in given with the first and second course only.
Patients responding to treatment or with stable disease are randomised to either:
1. Arm A: Three further cycles of MVP chemotherapy. Mitomycin-C is given with the first and third course only.
2. Arm B: Best supportive care.

## Intervention Type
Drug

## Phase
Not Specified

## Drug/device/biological/vaccine name(s)
Mitomycin-C, Vinblastine and Moderate Dose Cisplatin

## Primary outcome(s)
Not provided at time of registration

## Key secondary outcome(s))
Not provided at time of registration

## Completion date
31/12/2005

# Eligibility

### Key inclusion criteria
1. Histological evidence of non-small cell lung cancer
2. Stage IIIb or IV disease not eligible for neoadjuvant chemotherapy and/or radical radiotherapy
3. Performance status <2 (Zubrod-Eastern Cooperative Oncology Group [ECOG]-World Health Organisation [WHO] scale)
4. Adequate renal, bone marrow, and lung function tests unless due to metastatic disease
5. Patients must already have achieved symptom relief after three cycles of MVP chemotherapy
6. No uncontrolled infection
7. No previous conventional chemotherapy prior to MVP. One prior phase I/II new drug is allowed
8. No medical contraindications to treatment protocols

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Not Specified

### Sex
Not Specified

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
01/01/2000

### Date of final enrolment
31/12/2005

# Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre
### UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

# Sponsor information

**Organisation**
The Royal Marsden NHS Foundation Trust (UK)

**ROR**
https://ror.org/0008wzh48

# Funder(s)

**Funder type**
Hospital/treatment centre

**Funder Name**
Royal Marsden Hospital (UK)

# Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration